Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision

Trial Profile

An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KVD 001 (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions; First in man
  • Sponsors KalVista Pharmaceuticals
  • Most Recent Events

    • 15 Jul 2019 According to the KalVista Pharmaceuticals Media Release, results of this trial were published in a financial report.
    • 15 Jul 2019 According to KalVista Pharmaceuticals Media Release, data from this trial has been accepted for publication in Ophthalmology Retina.
    • 19 May 2016 Status changed from active, no longer recruiting to completed, as reported by KalVista media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top